Aptar Pharma’s Electronic Lockout Device Approved by EMA
Aptar Pharma’s e-Lockout device is the first and only fully integrated electronic nasal drug delivery device to be approved by a US or European regulatory authority.
Courtesy of Aptar Pharma
Aptar Pharma announced the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG.
Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl® used in pain management. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuard™.
Takeda will launch Instanyl DoseGuard™ in Europe in several multidose strengths, using Aptar Pharma’s patented electronic lockout system. The approval represents a major milestone for Aptar Pharma, with the e-Lockout device being the first and only fully integrated electronic nasal drug-delivery device to be approved by EMA.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit:www.aptar.com/pharma
To download the complete press release:
http://news.aptar.com/solutions/aptar-pharmas-electronic-lockout-device-approved-by-ema/
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
